Background
==========

Hypertension and hypercholesterolaemia are common problems in general practice and have important consequences for patients and the use of healthcare resources. In Norway the cost of prescription drugs for hypertension and hypercholesterolaemia accounts for 18% of the total public expenditure on drugs \[[@B1]\]. Cardiovascular disease is a common cause of death and an important cause of morbidity in Norway.

Appropriate use of antihypertensive and cholesterol-lowering drugs for the primary prevention of cardiovascular disease can have important benefits, whereas inappropriate prescribing entails substantial costs, as well as undesirable consequences for patients.

There is high quality evidence from well-designed randomised trials of the effects of antihypertensive and cholesterol-lowering drugs for the primary prevention of cardiovascular disease \[[@B2],[@B3]\]. There are also a number of clinical practice guidelines, often with conflicting recommendations, e.g on the choice of drug or threshold to start treatment \[[@B4]\]. Based on a review of previous guidelines and the underlying evidence, we developed guidelines for prescribing anthihypertensive and cholesterol-lowering drugs for the primary prevention of cardiovascular disease in Norwegian general practice \[[@B5]-[@B7]\].

There is potential for improvement for three key recommendations: cardiovascular risk is commonly not measured before starting treatment \[[@B8]\], thiazides are under-utilised when initiating treatment for hypertension \[[@B1]\], and treatment goals are frequently not achieved for both blood pressure and cholesterol \[[@B9],[@B10]\]. We have therefore developed an intervention aimed at supporting the implementation of these three recommendations and planned a trial to assess the effectiveness and costs of this intervention.

The results of evaluations of interventions to improve clinical practice vary and large effects are not common \[[@B11],[@B12]\]. As with any behaviour, professional behaviour is difficult to change. Several strategies have been used. Some of them, like passive dissemination of clinical practice guidelines, have little or no effect on practice \[[@B12],[@B13]\]. Other, more active strategies, like educational outreach visits \[[@B14]\] and multifaceted interventions \[[@B11]\], are more effective, but require more resources \[[@B11]\]. The underlying reasons for differences between clinical practice and systematically developed guidelines vary from one clinical problem to another and from one clinician to another \[[@B15],[@B16]\]. It is therefore logical to tailor strategies to support the implementation of guidelines to address identified barriers to change \[[@B15]\]. However, the effects of such interventions remain uncertain \[[@B16],[@B17]\]. They should be rigorously evaluated before they are widely used. Because the effects are expected to be moderate, at best, and biases, particularly non-equivalent comparison groups, can easily distort the results of evaluations, cluster-randomised trials (in which healthcare professionals or groups of professionals, rather than patients are randomised) are more likely to provide valid results than other research designs, such as controlled before-after or time-series studies \[[@B18]\].

Objectives
----------

The primary objective of this trial is to evaluate the effects of a tailored intervention to support the implementation of guidelines by Norwegian general practitioners for the use of antihypertensive and cholesterol-lowering drugs for the primary prevention of cardiovascular disease. Our hypothesis is that the tailored intervention will be more effective than passive dissemination of the guidelines at reducing the proportions of first time prescriptions for hypertension where thiazides are not prescribed, patients not assessed for cardiovascular risk before prescribing antihypertensive or cholesterol-lowering drugs, and patients treated for hypertension or high cholesterol for three months or more who have not achieved recommended treatment goals.

Secondary objectives are to estimate the use of resources associated with the intervention and the effects of the intervention on other relevant outcomes. We anticipate that passive dissemination of guidelines, which is unavoidable for published guidelines, will have little effect on the outcomes of interest \[[@B11]-[@B13]\] and is therefore an appropriate control-intervention.

A process evaluation, to understand the effects or lack of effects of the intervention, and an economic analysis, if the intervention is effective, are described in separate protocols.

Methods
=======

Design
------

The main hypotheses will be tested using a cluster-randomised controlled trial comparing outcomes between the intervention and control groups at follow up. General practices will be randomised to receive a tailored intervention to support implementing the guidelines or to a control group (see Figure [1](#F1){ref-type="fig"}). Data will be collected for all eligible patients from participating practices for one year after the outreach visit. For the control group data will be collected for one year after publication of the guidelines in the Journal of the Norwegian Medical Association.
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Participants
------------

All general practices in or near to Oslo or Tromsø in Norway that use one of two electronic medical record systems (WinMed or ProfDoc Vision) are eligible for the trial. Over 80% of Norwegian general practices use one of three electronic medical record systems, and these are used routinely during consultations. The two restrictions are pragmatic. 1) The computer software that will be used does not yet function with the third electronic medical record system. 2) We have recruited four pharmacists to carry out the outreach visits. Three of them live in the Oslo area and one near to Tromsø. We have chosen to recruit practices in the corresponding geographical areas. There are 388 general practices that meet these inclusion criteria. All of these practices will be invited to participate.

Intervention
------------

We developed our intervention through a process of identifying barriers to implementation of the recommendations and subsequently coming up with suggestions of measures that may facilitate change by specifically addressing the barriers (\"tailoring\"). This was mainly done through active reflection and discussions in a group of three physicians with experience from general practice (including two of the authors, AF and ADO). In order to structure the reflection we used a worksheet designed to facilitate the discussion by listing possible factors that may act as barriers within the practice environment, within the professional environment, and related to physicians\' knowledge, skills and attitudes \[[@B19]\]. We also took into account information gathered from a survey of general practitioners, experience from our own research, and from discussion with physicians during pilot testing of the intervention.

In order to identify previously executed trials of interventions targeted at the management of hypertension and/or elevated cholesterol in general practice, the trial register of the Cochrane Group of Effective Practice and Organisation of Care (EPOC) was searched in July 2001 (See [Additional File 1](#S1){ref-type="supplementary-material"}: Appendix) \[[@B20]\].

Table [1](#T1){ref-type="table"} describes the various elements of our intervention.

###### 

Elements of the tailored intervention

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --
  **Educational outreach visit**                                                                                                                                                                                                                                                   
   • Presentation focusing on three main messages:                                                                                                                                                                                                                                 
    1. Relevance of risk estimation and how to do it, including strategies on how to communicate information about risk to patients.                                                                                                                                               
    2. Information on evidence in support of effect and the unjustified fear of adverse effects regarding thiazides, pointing at the consensus that exists among guidelines. Attention also directed to the importance of clinically relevant endpoints when studies are quoted.   
    3. Clear recommendations justified by referring to high degree of consensus among guidelines.                                                                                                                                                                                  
   • Guidelines handed out, directing attention to the authors (opinion leaders)                                                                                                                                                                                                   
  **Audit & feed-back at outreach visit**                                                                                                                                                                                                                                          
   • To what extent treatment goals are achieved.                                                                                                                                                                                                                                  
   • Drug-choice profile on antihypertensives                                                                                                                                                                                                                                      
   • Level of risk among patients on treatment, compared to a sample (men 40--65 years) not on treatment                                                                                                                                                                           
  **Computerised reminders**                                                                                                                                                                                                                                                       
   • Risk assessment                                                                                                                                                                                                                                                               
   • First-choice antihypertensive drugs                                                                                                                                                                                                                                           
   • Treatment goals                                                                                                                                                                                                                                                               
  **Risk assessment tools as charts and in electronic format**                                                                                                                                                                                                                     
  **Patient-information material**                                                                                                                                                                                                                                                 
   • The relationship between single risk factors and global risk                                                                                                                                                                                                                  
   • Thiazides and beta-blockers.                                                                                                                                                                                                                                                  
   • Treatment goals                                                                                                                                                                                                                                                               
  **Follow-up**                                                                                                                                                                                                                                                                    
   • Telephone call to the practice within 1--3 days to check that software has not led to any difficulties                                                                                                                                                                        
   • Short telephone call to each physician after 1--3 months                                                                                                                                                                                                                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --

The practical implementation of the intervention will be initiated through an educational outreach visit carried out by pharmacists recruited specifically for this purpose. No specific qualifications will be demanded, and the pharmacists will be given the necessary training during two weeks in our department. This training will cover basic research methods, the content of the clinical practice guidelines, and two days dedicated to communication techniques.

During the outreach visit the main elements of the guideline will be presented, with special emphasis on risk estimation, choice of first-line drugs, and treatment goals. A printed copy of the guideline and a one-page version will be given to the physicians, including a chart to aid the estimation of cardiovascular risk.

During the visit a software package will be installed. This enables us to extract data and immediately, during the visit, present the physicians with data on their performance concerning risk estimation, choice of antihypertensive drugs and achievement of treatment goals (\"audit and feed-back\"). The software package also includes computerized reminders using \"pop-ups\" on the computer screen (see Figure [2](#F2){ref-type="fig"}). These are triggered at the patient\'s first visit following a recording of an elevated blood pressure- or cholesterol-level (blood pressure \> 140/90 mm Hg or total-cholesterol \> 5 mmol/L or LDL-cholesterol \> 3 mmol/L). The physician can easily close the \"pop-ups\" each time they appear. We will not record how often this is done.

![**Example of pop-up on physician\'s computer screen**. The pop-ups provide various reminders to the physician related to specific patients. For example, if the most recent blood pressure recorded within the last six months is above 140/90 mm Hg, the physician will be asked if antihypertensive therapy is being considered when the patient\'s medical record is opened. If the physician responds \"Yes\" the pop-up in the figure appears, which reminds the physician that thiazides are first-choice drug for most cases of uncomplicated hypertension and asks if he/she would like to prescribe a thiazide. If the response is \"Yes\" the next pop-up provides brand names of available thiazide-drugs.](1472-6963-3-5-2){#F2}

If the patient has not been prescribed blood-pressure- or cholesterol-lowering drugs the physician is reminded of the recommendation to carry out cardiovascular risk assessment and is offered to start a computerized risk assessment tool (SmartHeart). Recommendations on choice of drugs are also given and the physician is also given the option of printing out patient information material.

If the patient has been prescribed blood-pressure- or cholesterol-lowering drugs, the \"pop-up\" will remind the physician of recommended treatment goals and ask if the physician would like to print out patient information material.

At the outreach visit a follow-up phone-call with each individual physician will be scheduled for 1--3 months after the initial visit and will focus on what questions, problems or concerns the physicians may have.

The pharmacists will complete a questionnaire after each outreach visit, enquiring about technical problems, physician-attitudes, and the pharmacist\'s own impression of the session.

One to two days after the visit a member of the research team will call the office to confirm that they are not experiencing problems as a result of our visit.

Outcome measures
----------------

We have chosen three main outcome measures, all aimed at physician-behaviour regarding the pharmacological management of primary prevention of cardiovascular disease for the 12 months following the outreach visit. Patients with a recorded cardiovascular diagnosis are excluded, with the exception of the third main outcome. Because antihypertensive drugs are also being prescribed for the treatment of thyrotoxicosis and migraine, we have excluded data from patients where these diagnoses are recorded. Patients are considered as previously untreated if they have hypertension (blood pressure \> 140/90 mmHg) and/or hypercholesterolaemia (total-cholesterol \> 5 mmol/L or LDL-cholesterol \> 3 mmol/L) and no prescription for the corresponding medication has been recorded for 24 months preceding the outreach visit.

### Main outcomes

• The proportion of prescriptions of other antihypertensives than thiazides to patients who are being prescribed antihypertensive drugs for the first time. (Measurement: data drawn from the practice medical record system.)

• The proportion of patients where the level of cardiovascular risk has not been estimated among all those started on antihypertensive or cholesterol lowering treatment. (Method: Physicians are given the names of the patients they have put on treatment and are asked if the cardiovascular risk has been evaluated, and if so: what the level was.)

• Proportion of patients with a recorded level of cholesterol (total or LDL) or blood pressure not satisfying the specified treatment goals, among all patients on the corresponding treatment for at least three months. For cholesterol we have decided to also include patients on secondary prevention therapy since the treatment goals are similar. (Measurement: data drawn from the practice medical record system.)

### We will also investigate the following outcomes

• The proportion of patients reporting that they were not involved in the decision-making process before drug treatment for hypertension and/or elevated cholesterol was started. (Measurement: questionnaire sent to patients by their physician, and returned anonymously to the research team.)

• Level of risk among patients started on treatment. (Measurement: Data drawn from the practice medical record system, and entered into a version of the Framingham-equation \[[@B21]\].)

• Proportion of patients with risk under 20% receiving treatment among those receiving treatment. (Measurement: Data drawn for the practice medical record system, and entered into a version of the Framingham-equation.)

• Level of risk among patients not started on treatment where blood pressure and cholesterol level has been recorded. (Measurement: Data on drawn from the practice medical record system, and entered into a version of the Framingham-equation.)

• Proportion of prescriptions of other antihypertensives than thiazides and beta-blockers to patients who are being prescribed antihypertensive drugs for the first time. (Measurement: data drawn from the practice medical record system.)

• Proportion of angiotensin-II-receptor blockers and/or alpha-blockers among prescripions of antihypertensives to patients who are being prescribed antihypertensive drugs for the first time. (Measurement: data drawn from the practice medical record system.)

• Subgroup-analysis for patients with diabetes: Proportion of patients with a recorded level of cholesterol (total or LDL) or hypertension not satisfying the specified treatment goals, among all patients on the corresponding treatment. For cholesterol we have decided to also include patients on secondary prevention therapy since the treatment goals are similar. (Measurement: data drawn from the practice medical record system.)

• Proportion of patients not reaching the specified treatment goal for blood pressure (Measurement: data drawn from the practice medical record system.)

• Proportion of patients not reaching the specified treatment goal for cholesterol (Measurement: data drawn from the practice medical record system.)

Economic analysis
-----------------

We will record parameters that describe costs related to our intervention:

• Salary-costs for pharmacists

• Time spent arranging for appointments at the doctors\' practices

• Travel expenses in connection with each outreach visit

• Amount of physician-time spent at each visit

• Materials

• Training

• Other direct expenses related to the implementation of the intervention

The economic analysis, which will only be conducted if the intervention is effective, will be described in a separate protocol.

Pilot study
-----------

The intervention has been tested on a small group of general practitioners. The first 10 practices that receive the intervention will be excluded from the study and defined as a pilot-group if major practical problems arise.

Recruitment and randomisation
-----------------------------

Block-randomisation was done within each geographical stratum: the Oslo-area and Northern Norway. The size of the blocks varied randomly between 2, 4 and 6. A colleague not directly involved in our research project generated the allocation-list using software from <http://www.randomisation.com>. We gave her ID-numbers representing each recruited practice, and she informed us whether the practice was allocated to the intervention- or control-group.

Baseline data
-------------

Baseline data (12 months before the intervention) will be collected for all outcomes on prescribing and measurements of blood pressure or cholesterol.

Ethics
------

The doctors who are invited to participate in the study will be given information about the objectives of the study and the practical impact it may have on their practice. They will be told that they will be randomised to an experimental or control group. We will obtain written consent from all practices. The aim of this study is to improve quality of care and thus should not imply any risk for the patients affected by the study. It is difficult to imagine that our intervention could worsen the quality of care. We have presented the project for the Regional Committee of Research Ethics and they did not consider it necessary to submit the protocol for approval.

The Norwegian Data Inspectorate has approved the handling of data. In accordance with regulations we have assessed the risk of misuse of the data we will be collecting. The risk is minimal due to the fact that the data are linked to a reference number that can only be linked to the specific patient by accessing the computer-system at the practice of the patient\'s physician using a program developed for this task.

Sample size and statistics
--------------------------

In order to demonstrate a 25% relative reduction, with a power of 80% and a statistical significance level of 5%, in outcome measures between the control and intervention groups, we estimated a need for a sample of almost 140 practices in total (Cluster Randomisation Sample Size Calculator ver 1.0.2, Health Services Research Unit, Aberdeen University). We assumed that none of the main outcomes would be less than 50% in the control group and that the average number of patients included per practice would be around 10 per outcome measure (three patients per physician, and three physicians per practice). This was based on sales figures of anti-hypertensive drugs \[[@B1]\], a survey on the usage of risk assessment tools \[[@B8]\], published figures on achievement of treatment goals \[[@B9],[@B10]\], estimates on the prevalence of hypertension-treatment (9% of those aged over 25) \[[@B22]\], and data we previously had collected from a group of practices. The sample size also takes into account the need to adjust for intracluster correlation, which is a consequence of randomising at one level (clinical practices) and analysing at another (patients). The adjusting factor was conservatively estimated to be 0.2, based on data from a previous study \[[@B17]\].

We will carry out post-test comparisons between the intervention- and control-group using cluster-adjusted chi-square and T-tests. Analysis of covariance may be used to adjust for imbalance of baseline levels between the intervention- and control-groups \[[@B23]\].
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